The investment objective of the Scheme is to provide returns before expenses that closelycorrespond to the total returns of the NIFTY Healthcare Index subject to tracking errors.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| ETFs | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -6.4% | -4.5% | 7.43% | 9% | 4.77% | 3.06% | 17.61% | 17.47% | 12.15% | N/A | 12.44% |
| Category returns | -2.99% | -4.52% | -3.02% | -5.03% | -4.77% | -2.03% | 9% | 10.98% | 7.45% | 11.5% | N/A |
| Absolute returns | -6.4% | -4.5% | 7.43% | 9% | 4.77% | 6.23% | 62.75% | 90.51% | 77.49% | N/A | 88.99% |
| Rank within category | 250/268 | 96/252 | 11/241 | 16/228 | 19/207 | 30/162 | 11/134 | 14/112 | 10/81 | N/A | N/A |
| ETFs | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Yearly returns | N/A | -10.32% | 33.48% | 40.85% | -1.84% | 6.45% |
| Q1 returns | N/A | -5.4% | -4.57% | 13.5% | -8.4% | -2.89% |
| Q2 returns | N/A | -11.31% | 17.19% | 4.2% | 5.74% | 13.64% |
| Q3 returns | 2.36% | 9.72% | 9.14% | 17.58% | -2.06% | 0.09% |
| Q4 returns | -0.13% | -2.59% | 9.37% | 1.28% | 3.47% | -3.61% |
| Alpha | -0.0250406 |
| Beta | 0.9986 |
| Sharpe Ratio | 0.265983 |
| Sortino Ratio | 0.571867 |
| R-Squared | 0.9971 |
| Tracking Error | 0.0585 |
| Downside Risk | 17.3712 |
| Std. Deviation (Annualised) | 14.1598 |
| ETFs | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | -7.16% | -4.01% | 10.11% | 12.75% | 6.7% | 19.48% | N/A | N/A | 19.41% | 44.40 | 0.36 | 0.30 | Very High |
| Nippon India Nifty Pharma ETF | -4.12% | -0.09% | 14.11% | 16.17% | 15.52% | 19.28% | 12.79% | N/A | 12.07% | 1,736.44 | 0.23 | 0.30 | Very High |
| Motilal Oswal BSE Enhanced Value ETF | -3.37% | -6.03% | -9.38% | -9.5% | -0.01% | 18.7% | N/A | N/A | 26.28% | 146.61 | 0.43 | 0.20 | Very High |
| DSP Nifty PSU Bank ETF | -0.29% | -1.08% | -5.84% | -7.11% | 9.24% | 18.66% | N/A | N/A | 20.49% | 1,434.17 | 0.16 | 0.15 | Very High |
| ICICI Prudential Nifty PSU Bank ETF | -0.32% | -1.15% | -6.01% | -7.33% | 8.91% | 18.53% | N/A | N/A | 26.2% | 118.61 | 0.41 | 0.15 | Very High |
| Nippon India ETF Nifty PSU Bank BeES | -0.32% | -1.17% | -6.04% | -7.39% | 8.81% | 18.35% | 25.56% | 10.01% | 6.93% | 3,932.00 | 0.51 | 0.14 | Very High |
| Kotak Nifty PSU Bank ETF | -0.32% | -1.17% | -6.06% | -7.4% | 8.79% | 18.33% | 25.56% | 9.94% | 6.36% | 2,490.74 | 0.51 | 0.14 | Very High |
| Aditya Birla Sun Life Nifty Healthcare ETF | -6.38% | -4.45% | 7.53% | 9.15% | 4.95% | 18.01% | 0% | N/A | 12.85% | 74.67 | 0.20 | 0.27 | Very High |
| ICICI Prudential Nifty Healthcare ETF | -6.38% | -4.44% | 7.56% | 9.19% | 5% | 17.87% | 12.38% | N/A | 12.86% | 231.43 | 0.16 | 0.27 | Very High |
| Axis NIFTY Healthcare ETF Current | -6.4% | -4.5% | 7.43% | 9% | 4.77% | 17.61% | 12.15% | N/A | 12.44% | 23.07 | 0.44 | 0.27 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 17.00% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 10.44% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 7.43% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.82% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.69% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.65% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.24% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 6.12% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.36% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.08% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.55% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.11% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.75% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.54% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.51% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.37% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.28% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.04% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 1.76% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.25% |
| Clearing Corporation of India Ltd | Cash & Cash Equivalents and Net Assets | 0.32% | |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | -0.29% | |
| Total | 100.00% | ||
andik is a seasoned financial services professional with over two decades of experience, predominantly in the asset management space. Prior to joining Axis AMC, he was the Chief Investment Officer (CIO) at Avendus Capital Public Markets Alternate Strategies LLP. Notably, Nandik also led the successful launch of the Long Short Fund at ICICI Prudential AMC, further cementing his expertise in innovative investment strategies.Educational Qualification: PGDM in Finance from IIM Calcutta, Master's Degree in Finance from London Business School, and BTech from IIT Kharagpur.
Mr. Rohit Kumar Gautam has an experience of over 13 years in his professional career. He joined as the "Head Research" in Shriram Asset Management Company Limited in June, 2019. Prior to joining Shriram, he was associated with APRRUS Foods and Beverages Pvt. Ltd., Firestar International Pvt. Ltd., Pythhos Technology Pvt. Ltd./Boston Analytics, Hangout Adventures where he had held various key positions in Research & Analysis, Corporate Strategy & Planning Professional, etc.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
